secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-275867
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva Q3 net loss $21.5M; AlloNK gets FDA Fast Track for RA
------------------------------------------------------------

- Over 100 patients dosed with AlloNK; FDA Fast Track Designation for refractory RA with rituximab.
- Initial response data for >15 refractory RA patients expected 1H 2026; FDA discussions planned.
- Cash, equivalents, investments $123M as of Sep 30, 2025; runway into Q2 2027.
- Q3 R&D expense $17.6M, G&A $5.3M; net loss $21.5M vs $17.5M year ago.
- CFO Neha Krishnamohan to step down end of Dec, advisory role; successor search underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312525275867/0001193125-25-275867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312525275867/artv-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-275867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer